Oakwell Private Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-8,163
Closed -$702K 74
2024
Q4
$702K Buy
8,163
+904
+12% +$97.8K 0.2% 41
2024
Q3
$864K Buy
7,259
+2,327
+47% +$310K 0.25% 37
2024
Q2
$704K Buy
4,932
+1,180
+31% +$156K 0.2% 40
2024
Q1
$482K Buy
3,752
+103
+3% +$12.3K 0.15% 43
2023
Q4
$377K Buy
+3,649
New +$361K 0.13% 45

Other funds holding NVO

Oakwell Private Wealth Management's NVO Position: Q1 2025 in Review

Oakwell Private Wealth Management sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 8,163 shares — an estimated $702K sold.

Oakwell Private Wealth Management first reported a position in NVO in Q4 2023 and held it in 5 quarters. The position peaked at $864K in Q3 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Oakwell Private Wealth Management reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Oakwell Private Wealth Management sold 8,163 Novo Nordisk shares in Q1 2025, an estimated $702K.
  • Oakwell Private Wealth Management first reported a position in Novo Nordisk in Q4 2023 and held it in 5 quarters.
  • Oakwell Private Wealth Management's Novo Nordisk position peaked at $864K in Q3 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Oakwell Private Wealth Management's 13F filing for Q1 2025, filed 6 May 2025.